Lipo-C
Lipotropic / MIC+B12 blend
Lipo-C (Lipotropic / MIC+B12 blend) is a metabolic & fat loss research compound. Methionine-inositol-choline plus B12 — supports fat metabolism and liver fat handling.
Lipo-C quick facts
| Reported research dose | .5ml-1ml |
| Route | Either |
| Frequency | 1x Daily Pre Exercise · Daily ( On Workout Days) |
| Half-life | Varies by component |
| Forms | Injectable |
| Evidence level | Anecdotal + supplement |
Fat-loss support shot, best pre-exercise. A helper, not a driver.
How Lipo-C works
Methionine-inositol-choline plus B12 — supports fat metabolism and liver fat handling.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get Lipo-C
Buy Lipo-C at Ion Peptide →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Lipo-C
Graded by what exists behind each claim.
✅ Clinically validated
- No randomized trial of the combination for fat loss. The individual components have real but separate literatures: B12 has unambiguous evidence in deficiency and none for fat loss in replete people; choline is an essential nutrient with evidence in hepatic steatosis; inositol has trial data in PCOS-related insulin resistance.
- A lipotropic injection has never been shown in a controlled trial to cause fat loss, and that is the honest headline.
📊 Correlative data
- Very widely administered in clinics, usually alongside a calorie deficit and often alongside a GLP-1 — which makes attribution nearly impossible, since the intervention it accompanies is one that reliably causes weight loss on its own.
- Well tolerated. Reported energy improvement is real and most likely explained by the B12 in anyone who was actually low.
🧪 Theoretical / extrapolated
- Methionine, inositol and choline plus B12. Methionine and choline are methyl donors required for phosphatidylcholine synthesis, which the liver needs to package and export fat as VLDL — choline deficiency causes hepatic steatosis in humans, so the liver mechanism is real.
- Supporting fat export from the liver is not the same as burning fat from the body. The mechanism is coherent for hepatic fat handling and does not extend to adipose tissue, which is where the marketing takes it.
- The strongest honest use of this is correcting a genuine deficiency — which is worth testing for rather than assuming.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Lipo-C actually does
The first honest sentence about Lipo-C is that it is not a molecule. It is a compounded blend — methionine, inositol and choline plus cyanocobalamin, sometimes with L-carnitine or other B vitamins — and there is no standard formula. Two clinics’ vials can differ in composition and in milligrams per milliliter, and neither usually publishes either. So the honest mechanism section takes the components one at a time and asks what each is actually known to do.
Choline: real biochemistry, and it is the reason the liver claim is not nonsense. Choline is the head group of phosphatidylcholine, and phosphatidylcholine is what a hepatocyte must have to assemble and export a VLDL particle. There are exactly two routes to it. The CDP-choline (Kennedy) pathway runs from dietary choline, and its rate-limiting and regulated step is CTP:phosphocholine cytidylyltransferase, an amphitropic enzyme that senses membrane composition and controls phospholipid homeostasis directly Cornell 2015. The second route is PEMT, which methylates phosphatidylethanolamine three times using S-adenosylmethionine. Block both and triglyceride accumulates inside the hepatocyte because it cannot be packaged for export. That is why choline deficiency causes hepatic steatosis in humans.
Methionine: the same product by the other road. Methionine is the precursor of SAM, and SAM is the methyl donor the PEMT route spends. So methionine and choline in the same syringe are not two unrelated nutrients — they converge on one product, phosphatidylcholine, by two different pathways. That convergence is the only genuinely coherent pharmacological idea in the formula.
And the human relevance of the PEMT arm is measured, not assumed. Piras 2022 found hepatic PEMT expression reduced in NAFLD patients with inflammation and fibrosis (β = −1.497, p = 0.005), declining further with increasing fibrosis severity (β = −1.185, p = 0.011). And Wu 2023 reports that the PEMT rs7946 polymorphism and sex modify the effect of adequate dietary choline intake on the risk of hepatic steatosis in older patients with metabolic disorders. Put those together and the picture is specific: the sicker the liver, the less PEMT it has, and how much choline you need depends on your genotype and your sex. That is a real, personalized, testable mechanism — and it is about hepatic fat, not about body fat.
Inositol is in a different pathway entirely, and nobody says so. Inositol is a cyclitol — the backbone of phosphatidylinositol and the source of the IP3 second messenger. It is not a methyl donor and it plays no part in the Kennedy or PEMT routes. Its human trial literature is in insulin resistance and polycystic ovary syndrome, which is a different biology from hepatic fat export. Its presence in the vial is a formulation tradition, not a pathway.
B12 is the one component with a defensible reason to be in a syringe, and its link to methionine is exact. Cobalamin is the cofactor for methionine synthase, the enzyme that regenerates methionine from homocysteine. So the B12 in the vial is the enzyme cofactor for recycling the by-product of the methionine in the same vial. Whether that balance nets out is the measurable question this page keeps returning to.
The gap the whole formula sits on, stated in one sentence. Every mechanism above governs whether the liver can package triglyceride and ship it out. Shipping it out puts it in the blood, where it goes to tissues — including adipose. There is no step anywhere in this biochemistry that removes fat from the body. Hepatic fat export and whole-body fat loss are different processes, and the formula only touches the first.
Cell, rodent, human — and where it stops
Step one, enzymology. CCT is the rate-limiting, regulated step in phosphatidylcholine synthesis and it controls membrane biogenesis directly Cornell 2015. Settled biochemistry, decades old.
Step two, human liver tissue. Piras 2022 measured hepatic PEMT expression across NAFLD severity and found it reduced with inflammation and fibrosis (p = 0.005) and declining as fibrosis worsened (p = 0.011). Human, quantitative, and directly relevant to the claimed mechanism.
Step three, human genetics. Wu 2023 shows the PEMT rs7946 polymorphism and sex modify how much protection adequate dietary choline intake gives against hepatic steatosis. Choline requirement is not one number for everybody, which is exactly why the scoping review prepared to set intake recommendations was a substantial undertaking Obeid 2023.
Step four, a controlled human methionine experiment — and it runs the wrong way for this product. Verhoef 2004 gave people a 30 mg/kg body weight methionine load and measured what happened downstream: peak total homocysteine reached 17.9 µmol/L on methionine alone. Adding serine brought the peak down to 14.3 µmol/L and cystine to 14.8 µmol/L, with the combined homocysteine curves 77% smaller (p < 0.0005). Methionine raises homocysteine in people, reliably, and the effect is modifiable by other amino acids.
Step five, the epidemiology of the other end of the choline pathway. Gut microbes convert choline to trimethylamine, which the liver oxidizes to TMAO. Tang 2013 measured plasma TMAO in 4,007 patients undergoing coronary angiography and found the highest versus lowest quartile hazard ratio for major adverse cardiovascular events was 2.54 (95% CI 1.96–3.28, P < 0.001). Observational, and one of the largest datasets either component has generated in humans.
Step six, carnitine where it is included. Alhasaniah 2023 describes carnitine’s role in energy production and fatty acid metabolism and concludes that supplementation may benefit primary carnitine deficits and certain secondary deficiencies, with findings that must be viewed with caution. Deficiency correction, again, rather than enhancement.
The obstacle, stated exactly: the trial does not exist. Every step above is real human science about a component. There is no randomized controlled trial of the injected combination — not for weight, not for body composition, not for hepatic fat, not for anything. And the setting makes the absence worse rather than better: the injection is almost always administered inside a calorie deficit and frequently alongside a GLP-1 receptor agonist, both of which cause weight loss on their own. An intervention given only alongside interventions that work cannot be evaluated by observing that people lose weight. That is not a gap in the literature; it is a design that makes attribution impossible.
Lipo-C pharmacokinetics — how much of it actually gets in
Route: intramuscular or subcutaneous, 0.5 to 1 mL — and the striking thing is that the route bypasses a barrier that does not exist. Choline, methionine and inositol are all well absorbed by mouth; they are dietary constituents, not drugs with a first-pass problem. The one component with a genuine reason to be injected is B12, and only in malabsorption — pernicious anemia, post-gastrectomy, ileal disease — where the intrinsic-factor route has failed. For everybody else the injectable route buys nothing pharmacokinetic over swallowing the same molecules.
The dose problem is a disclosure problem. What is specified for this product is a volume, 0.5 to 1 mL, and what is usually not specified is milligrams per milliliter of anything. Choline requirement is set in the hundreds of milligrams per day — setting that figure was substantial enough to warrant its own scoping review Obeid 2023 — and one milliliter of an aqueous solution has a hard ceiling on how much of a highly soluble small molecule it can carry alongside three other actives. Without a certificate of analysis, the delivered dose of the component with the strongest mechanism cannot be compared with a single egg.
What clears each component, because they are not the same. Choline has three fates: phosphorylation into the Kennedy pathway Cornell 2015; oxidation to betaine, where it acts as a methyl donor; and bacterial conversion to trimethylamine in the gut, followed by hepatic oxidation to TMAO Tang 2013. Methionine enters the transmethylation cycle — SAM, then S-adenosylhomocysteine, then homocysteine — which is either remethylated by the B12-dependent methionine synthase or committed to transsulfuration Verhoef 2004. Inositol is largely handled by renal clearance and reabsorption. B12 is bound to transport proteins, stored hepatically and recirculated, which is why a serum level alone is a poor status marker and why the interpretation of B12 biomarkers needs a review of its own Harrington 2024. Four components, four disposal routes, one syringe.
The one hard human number, and what it constrains. A 30 mg/kg oral methionine load produced a peak homocysteine of 17.9 µmol/L Verhoef 2004. For a 70 kg adult that load is about 2.1 grams of methionine — far more than any 1 mL injection can contain. So the arithmetic cuts in the product’s favor on this specific point: the methionine dose in a lipotropic injection is almost certainly too small to produce a load-test homocysteine spike. What it does over repeated weekly dosing, against B12 pushing in the opposite direction, is a different question — and it has never been measured.
What would have to be true, and how you would know it was not
Four predictions. Two are cheap markers nobody has ever drawn on this product, and the last one is the design that would settle whether it does anything at all.
1. If B12 is the component actually doing the work, the functional markers say so and the serum level does not. Draw vitamin B12, methylmalonic acid (MMA) and homocysteine before the first injection. Serum B12 will rise after an injection whether or not you needed it — that is not information. MMA is the functional marker: it is elevated in true deficiency and falls when the deficiency is corrected, and its interpretation alongside the other biomarkers is precisely what Harrington 2024 exists to explain. The falsifiable claim: in a replete person, B12 rises and MMA does not move, because it was never high — and any reported energy improvement in that person is not a B12 effect.
2. Homocysteine is the marker with two forces pulling on it, which is what makes it worth drawing. Methionine pushes it up — a load produced a peak of 17.9 µmol/L Verhoef 2004 — and the B12 in the same vial pushes it down by supplying the methionine synthase cofactor. Nobody knows the net direction after eight weeks of weekly injections, because nobody has measured it. Draw homocysteine at baseline and at 8 weeks, holding folate and B6 intake constant. Either answer is new information about this product.
3. The prediction nobody has ever tested, and it is a cardiovascular one. Choline is the substrate for gut microbial trimethylamine production and hepatic conversion to TMAO, whose highest-quartile hazard ratio for major adverse cardiovascular events was 2.54 in 4,007 people Tang 2013 — and carnitine, where the formula includes it, is a second TMAO precursor Alhasaniah 2023. So the mechanistic prediction is that repeated choline dosing raises plasma TMAO. It is a commercially available assay, it is directly downstream of the main ingredient, and not one measurement of it after a lipotropic injection has ever been published. This is the single most valuable draw on the page.
4. And the prediction that cuts against the product entirely: matched for calorie deficit, the injection should add nothing to the scale. The mechanism governs hepatic phosphatidylcholine synthesis and VLDL export Cornell 2015; there is no step in it that oxidizes adipose triglyceride. The clean personal test is an 8-week block on the deficit alone followed by an 8-week block on the same deficit plus injections, with the same weighing protocol, the same intake tracking and the same training. The prediction is no difference beyond measurement noise. If someone runs that and finds a difference, it is genuinely interesting — because no controlled trial has ever found one.
What nobody has tested yet
Nobody has run a randomized controlled trial of the injected combination, for any endpoint. Not fat loss, not hepatic fat, not energy. This is a product administered in clinics at scale, for decades, and the trial that would settle it — two arms, a matched calorie deficit in both, injections against saline, weight and a liver-fat imaging endpoint at 12 weeks — has never been published. The absence is not a knowledge gap in a difficult field. It is an easy study nobody has commissioned.
Nobody has measured TMAO or homocysteine after a course of these injections. Both are the direct downstream consequences of the two main ingredients Tang 2013 Verhoef 2004, both are orderable assays, and both are unmeasured in this context. Twenty people with before-and-after draws would produce more human data about the metabolic consequences of lipotropic injections than currently exists.
Nobody has stratified a choline trial by PEMT genotype with an imaging endpoint. Wu 2023 establishes that rs7946 and sex modify the effect of choline intake on hepatic steatosis, and Piras 2022 establishes that hepatic PEMT expression falls as liver disease worsens. Together they predict that a choline intervention for liver fat should work best in a definable subgroup — and every trial run so far has been unstratified, which is a design guaranteed to dilute a real effect into a null result.
And nobody has published what is in the vial. The single most useful thing any clinic could do for this product is release a certificate of analysis: milligrams per milliliter of methionine, inositol, choline and cyanocobalamin, plus the preservative. Without it, two people comparing experiences are not comparing the same compound, and no experiment run on one clinic’s vial generalizes to another’s.
Lipo-C — its own safety story, not its class's
Start with what is true: the components are nutrients and the risk profile is not toxicity. Choline, methionine, inositol and cyanocobalamin are dietary constituents with established metabolic roles, and the realistic acute problems with this product are injection-site pain and irritation — methionine solutions sting — and the ordinary hazards of any intramuscular injection. That is the honest headline and it should not be dressed up.
The compounding question is the specific one, and it is not about the actives. This is a compounded, non-standardized preparation. Sterility, endotoxin content, pH, and the identity and quantity of the preservative are not verifiable by the person receiving it, and there is no monograph to check a batch against. Every risk in that sentence belongs to the preparation, not to methionine or choline.
The two metabolic questions that are genuinely open, and neither appears on any lipotropic page. First, homocysteine: methionine raises it in controlled human loading studies Verhoef 2004, B12 lowers it, and the net effect of repeated injections containing both has never been measured. Second, TMAO: choline is its precursor, carnitine is another Alhasaniah 2023, and plasma TMAO in the top quartile carried a hazard ratio of 2.54 for major adverse cardiovascular events in 4,007 people Tang 2013. That is an association in a high-risk angiography population and not proof of causation — but it is a specific, named, cheaply measurable concern attached to the main ingredient, and the absence of a single published measurement is the finding.
The B12 risk is diagnostic rather than toxic, and it is worth spelling out. Excess B12 is excreted and does not accumulate harmfully. What empirical injection can do is normalize a serum level and mask the picture of a deficiency whose cause was never established — malabsorption, pernicious anemia, metformin use — and interpreting B12 status properly requires more than one number Harrington 2024. A person who felt better after their first injection has learned something important about themselves and should find out what it was, rather than buying a course of the blend.
And the risk that has nothing to do with pharmacology. The injection is given alongside a calorie deficit and often alongside a GLP-1 receptor agonist. It will be credited with the result. That misattribution is the largest real cost here: it is money spent on the component of a protocol least likely to be responsible for the outcome, and it makes the person less able to work out what actually helped them.
Sources read for this page
- Cornell RB. CTP:phosphocholine cytidylyltransferase: Function, regulation, and structure of an amphitropic enzyme required for membrane biogenesis.. Prog Lipid Res 2015 · PMID 26165797
- Piras IS. Hepatic PEMT Expression Decreases with Increasing NAFLD Severity.. Int J Mol Sci 2022 · PMID 36012560
- Wu CH. PEMT rs7946 Polymorphism and Sex Modify the Effect of Adequate Dietary Choline Intake on the Risk of Hepatic Steatosis in Older Patients with Metabolic Disorders.. Nutrients 2023 · PMID 37513629
- Verhoef P. Dietary serine and cystine attenuate the homocysteine-raising effect of dietary methionine. Am J Clin Nutr 2004 · PMID 15321808
- Tang WH. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.. N Engl J Med 2013 · PMID 23614584
- Obeid R. Choline - a scoping review for Nordic Nutrition Recommendations 2023.. Food Nutr Res 2023 · PMID 38187796
- Harrington DJ. The application and interpretation of laboratory biomarkers for the evaluation of vitamin B12 status. Ann Clin Biochem 2024 · PMID 39367523
- Alhasaniah AH. l-carnitine: Nutrition, pathology, and health benefits.. Saudi J Biol Sci 2023 · PMID 36632072
Lipo-C — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- A lipotropic / metabolic-cofactor blend — B-vitamins, methyl donors and carnitine in varying combinations.
- *the metabolic-cofactor arm:* These act on mitochondrial function, NAD+ availability, sirtuin signaling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- *the metabolic-cofactor arm:* Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- *the metabolic-cofactor arm:* The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
- The methyl-donor arm is the one to know about. If you carry an MTHFR variant, or already supplement methylfolate and B12, this adds to that pool rather than starting it — and homocysteine is the marker that reads the result.
- The risk that belongs to the blend rather than any component: double-dosing. If you already run any of the peptides above separately, adding this blend means two doses of it — and almost nobody counts a blend's arms against what is already in their protocol. Read the composition against your current stack before the first injection.
What has actually been reported
- *the metabolic-cofactor arm:* Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- *the metabolic-cofactor arm:* The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Same mechanism as the prediction.
- *the metabolic-cofactor arm:* Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- *the metabolic-cofactor arm:* Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- *the metabolic-cofactor arm:* Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- *the metabolic-cofactor arm:* Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay.
- *the metabolic-cofactor arm:* There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- *the metabolic-cofactor arm:* Active malignancy, for the survival-signaling reasoning above.
- *the metabolic-cofactor arm:* Pregnancy — uncharacterized.
The honest unknown
- *the metabolic-cofactor arm:* Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalog should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Lipo-C — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Lipo-C moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
From the lipotropic arm. Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
From the lipotropic arm. Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
From the lipotropic arm. Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
A lipotropic / metabolic-cofactor blend — B-vitamins, methyl donors and carnitine in various combinations. The methyl-donor arm is the one worth knowing about: if you carry an MTHFR variant or are already supplementing methylfolate and B12, you are adding to that pool rather than starting it, and homocysteine is the marker that reads the result.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Lipo-C in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Lipo-C
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
Lipo-C — frequently asked questions
What is Lipo-C?
Lipo-C (Lipotropic / MIC+B12 blend) is a metabolic & fat loss research compound. Methionine-inositol-choline plus B12 — supports fat metabolism and liver fat handling.
Is the full Lipo-C protocol on this page?
The reported research dose is on this page, along with how Lipo-C works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Lipo-C?
Lipo-C has an approximate half-life of Varies by component, which is part of what determines how often it's dosed.
What's the evidence behind Lipo-C?
Current evidence level: Anecdotal + supplement. Lipo-C is offered for research purposes only and is not an approved medicine.
Lipo-C inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Lipo-C is used for
Lipo-C appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
Lipo-C is the hepatic arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.